| General Information | |
|---|---|
| ZINC ID | ZINC000169322717 |
| Molecular Weight (Da) | 399 |
| SMILES | O=C1/C(=C/c2cccc(OCc3ccccc3Cl)c2)N=C2SCCCCN12 |
| Molecular Formula | C21Cl1N2O2S1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 111.492 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 27 |
| LogP | 5.101 |
| Activity (Ki) in nM | 2290.87 |
| Polar Surface Area (PSA) | 67.2 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.154 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.24 |
| Ilogp | 3.75 |
| Xlogp3 | 5.04 |
| Wlogp | 3.96 |
| Mlogp | 3.7 |
| Silicos-it log p | 5.33 |
| Consensus log p | 4.36 |
| Esol log s | -5.55 |
| Esol solubility (mg/ml) | 0.00112 |
| Esol solubility (mol/l) | 0.0000028 |
| Esol class | Moderately |
| Ali log s | -6.19 |
| Ali solubility (mg/ml) | 0.000256 |
| Ali solubility (mol/l) | 0.00000064 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.94 |
| Silicos-it solubility (mg/ml) | 0.0000462 |
| Silicos-it solubility (mol/l) | 0.00000011 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.15 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 1 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.74 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.915 |
| Logd | 4.158 |
| Logp | 4.466 |
| F (20%) | 0.001 |
| F (30%) | 0.004 |
| Mdck | - |
| Ppb | 100.14% |
| Vdss | 0.956 |
| Fu | 1.16% |
| Cyp1a2-inh | 0.966 |
| Cyp1a2-sub | 0.319 |
| Cyp2c19-inh | 0.902 |
| Cyp2c19-sub | 0.075 |
| Cl | 5.007 |
| T12 | 0.068 |
| H-ht | 0.869 |
| Dili | 0.957 |
| Roa | 0.153 |
| Fdamdd | 0.846 |
| Skinsen | 0.233 |
| Ec | 0.003 |
| Ei | 0.013 |
| Respiratory | 0.063 |
| Bcf | 2.734 |
| Igc50 | 4.617 |
| Lc50 | 6.211 |
| Lc50dm | 6.014 |
| Nr-ar | 0.011 |
| Nr-ar-lbd | 0.062 |
| Nr-ahr | 0.944 |
| Nr-aromatase | 0.98 |
| Nr-er | 0.971 |
| Nr-er-lbd | 0.424 |
| Nr-ppar-gamma | 0.203 |
| Sr-are | 0.914 |
| Sr-atad5 | 0.699 |
| Sr-hse | 0.527 |
| Sr-mmp | 0.945 |
| Sr-p53 | 0.929 |
| Vol | 387.112 |
| Dense | 1.028 |
| Flex | 0.16 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 4 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.681 |
| Synth | 2.556 |
| Fsp3 | 0.238 |
| Mce-18 | 46.154 |
| Natural product-likeness | -1.413 |
| Alarm nmr | 4 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |